个人信息
Personal Information
联系方式
Contact Information
个人简介
Personal Profile
尹琳琳，博士，研究员，博士研究生导师。现任国家神经系统疾病临床医学研究中心基础与转化医学中心、神经病学中心神经感染与免疫科实验室负责人；主要研究方向：神经免疫疾病的发病机制、体液标记物筛选、新药物干预靶点的研究与发现。先后主持或作为课题骨干承担国家自然科学基金等国家级项目5项（82271374，81830038，81341088，81001656，81273498），主持或承担北京市自然科学基金面上项目（7162208，7212030，7212029）3项，主持首都卫生发展科研专项自主创新项目（首发2011-1001-06）1项。2012年入选北京市科技新星计划（Z12111000250000）1项、北京市委组织部优秀人才（2012D005018000010）1项，2014年入选北京市卫生系统高层次技术人才（学科骨干）（2014-3-052）1项。已发表论文50余篇，代表性第一或通讯作者SCI论文30余篇，担任SCI期刊Froniters in immunology、Froniters in Pharmacology、Biochemistry and Behavior、Neurological Research等期刊审稿人，国家自然科学基金面上项目通讯评审专家，教育部学位中心评审专家，北京市科委科技项目通讯评审专家。参编教材及专著4部；申报专利5项，其中2项获发明专利授权、1项获实用新型授权，进入美国获国际PCT授权2项。主要社会任职包括：北京神经内科学会理事；北京神经内科学会基础与转化医学专业委员会副主任委员、常委；北京神经内科学会感染与免疫专业委员会委员；北京药学会老年药学专业委员会委员；中国医药生物技术协会实验室建设与管理分会委员。
尹琳琳教授所在神经感染与免疫实验室，依托国家神经系统疾病临床医学研究中心基础与转化医学中心实验室，占地面积2410 m2，具有组织、细胞、蛋白、分子、流式、光学影像、小动物行为、脂代谢与动脉粥样硬化中心、公共基础实验区等9个实验平台，拥有300万元以上大型仪器设备10余台，实验设备总价值超过1.3亿。能够实现从活体动物到细胞、分子的实时动态观察及机制研究，为产出高水平的研究成果提供硬件支持。
1. 国家自然科学基金重点项目，脑出血后小胶质细胞与脑水肿发生的机制和临床意义（81830038），2019.1~2023.12，参与，在研
2. 国家自然科学基金面上项目，吲哚丙烯酸对MOG抗体相关疾病小胶质细胞激活和神经炎症的调控及临床意义（82271374），2023.1~2026.12，参与，在研
3. 北京市自然科学基金面上项目，CCL2在NMOSD致病性抗体NMO-IgG攻击星型胶质细胞中的作用及机制研究（7212030），2021.01-2023.12，主持，在研
4. 北京市自然科学基金面上项目，TREM2在首次发病的视神经脊髓炎谱系疾病所致神经功能损伤中的作用及机制研究（7212029），
2021.01-2023.12，参与，在研
近5年代表性文章
1. Bian J, Sun J, Chang H, Wei Y, Cong H, YaoM, Xiao F, Wang H, Zhao Y, Liu J, Zhang X, Yin L. Profile and potential role ofnovel metabolite biomarkers, especially indoleacrylic acid, in pathogenesis ofneuromyelitis optica spectrum disorders. Front Pharmacol. 2023 May19;14:1166085. doi: 10.3389/fphar.2023.1166085.
2. Chang H, Ma J, Feng K, Feng N, Wang X, SunJ, Guo T, Wei Y, Xu Y, Wang H, Yin L, Zhang X. Elevated blood and cerebrospinalfluid biomarkers of microglial activation and blood‒brain barrier disruption inanti-NMDA receptor encephalitis. J Neuroinflammation. 2023 Jul 22;20(1):172.doi: 10.1186/s12974-023-02841-7.
3. Wang Y, Bian J, Yao M, Du L, Xu Y, ChangH, Cong H, Wei Y, Xu W, Wang H, Zhang X, Geng X, Yin L*. Targetingchemoattractant chemokine (C-C motif) ligand 2 derived from astrocytes is apromising therapeutic approach in the treatment of neuromyelitis opticaspectrum disorders. Front Immunol. 2023; 14: 1144532. doi:10.3389/fimmu.2023.1144532.
4. Wang Y, Zhang J, Chang H, Wang H, Xu W,Cong H, Zhang X, Liu J, Yin L*. NMO-IgG Induce Interleukin-6Release via Activation of the NF-κB Signaling Pathway in Astrocytes. Neuroscience. 2022; 496: 96-104. doi:10.1016/j.neuroscience.2022.05.038.
5. Wang Y, Chang H, Zhang X*, Yin L*.Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders:An update systematic review and meta -analysis. Mult Scler Relat Disord 2021;50: 102843. doi: 10.1016/j.msard.2021.102843.
6. Wang Y, Ma J, Chang H, Zhang X*, YinL*. Efficacy of mycophenolate mofetil in the treatment of neuromyelitisoptica spectrum disorders: An update systematic review and meta -analysis. MultScler Relat Disord 2021; 55: 103181. doi: 10.1016/j.msard.2021.103181.
7. Chang H#, Cong H#, Wang H, Du L, Tian DC,Ma Y, Xu Y, Wang Y, Yin L*, Zhang X*. Thymic Involution andAltered Naive CD4 T Cell Homeostasis in Neuromyelitis Optica Spectrum Disorder.Front Immunol. 2021; 12: 645277. doi:10.3389/fimmu.2021.645277.
8. Cong H, Liang M, Wang Y, Chang H, Du L,Zhang X, Yin L*. Icariin ameliorates the cuprizone-induced acutebrain demyelination and modulates the number of oligodendrocytes, microglia andastrocytes in the brain of C57BL/6 mice. Brain ResBull. 2021; 175: 37-47. doi: 10.1016/j.brainresbull.2021.07.010.
9. Du L, Chang H, Xu W, Zhang X*, YinL*. Elevated chemokines and cytokines for eosinophils in neuromyelitisoptica spectrum disorders. Mult Scler Relat Disord. 2021; 52: 102940.doi: 10.1016/j.msard.2021.102940.
10. Du L,Chang H, Xu W, Wei Y, Wang Y, Yin L*, Zhang X*. Effect of NMO-IgGon the interleukin-6 cascade in astrocytes via activation of the JAK/STAT3signaling pathway. Life Sci. 2020; 258:118217. DOI: 10.1016/j.lfs.2020.118217
11. Du L,Chang H, Wei Y, Zhang X*, Yin L*. Different Roles of Soluble CD40Ligand in Central Nervous System Damage. Neurol Res, 2020; 42(5): 372-378.
12. Li W,Chang H, Wu W, Xu D, Jiang M, Gao J, Huang Y, Xu Y, Yin L*, ZhangX*. Increased CSF Soluble TREM2 Concentration in Patients with Neurosyphilis. FrontNeurol, 2020; 11, 62.
13. Cong H,Zhang M, Chang H, Du L, Zhang X, Yin L*. Icariin ameliorates theprogression of experimental autoimmune encephalomyelitis by down-regulating themajor inflammatory signal pathways in a mouse relapse-remission model ofmultiple sclerosis. EurJ Pharmacol. 2020; 885: 173523. doi:10.1016/j.ejphar.2020.173523.
14. Wei Y,Chang H, Feng H, Li X, Zhang X, Yin L*.Low Serum Interleukin-10 Is an Independent Predictive Factor for the Risk ofSecond Event in Clinically Isolated Syndromes. Front Neurol. 2019; 10: 604.doi: 10.3389/fneur.2019.00604.
15. ChangH, Wei Y, Chen Y, Du L, Cong H, Zhang X, Geng X, Yin L*. The antipsychotic-like effects of clozapinein C57BL/6 mice exposed to cuprizone: Decreased glial activation. Behav Brain Res. 2019; 364: 157-161.
16. Qu Z,Zheng N, Wei Y, Chen Y, Zhang Y, Zhang M, Chang H, Liu J, Ai H, Geng X, Wang Q,Yin L*. Effect ofcornel iridoid glycoside on microglia activation through suppression of theJAK/STAT signaling pathway. J Neuroimmunol. 2019; 330: 96-107.
17. Wei Y, Chang H, Li X, Wang H, Du L, Zhou H,Xu W, Ma Y, Yin L*, Zhang X.Cytokines and Tissue Damage Biomarkers in First-Onset Neuromyelitis Optica SpectrumDisorders: Significance of Interleukin-6. Neuroimmunomodulation. 2018;25(4): 215-224.
18. Wei Y,Chang H, Li X, Du L, Xu W, Cong H, Yao Y, Zhang X, Yin L*. CSF-S100B Is a Potential Candidate Biomarker forNeuromyelitis Optica Spectrum Disorders. Biomed Res Int. 2018; 2018: 5381239.
文件上传中...
